These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 37953801)
1. Role of Tau protein in long COVID and potential therapeutic targets. Marwaha B Front Cell Infect Microbiol; 2023; 13():1280600. PubMed ID: 37953801 [TBL] [Abstract][Full Text] [Related]
2. Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected. Ferrara F; Zovi A; Masi M; Langella R; Trama U; Boccellino M; Vitiello A Naunyn Schmiedebergs Arch Pharmacol; 2023 Jul; 396(7):1583-1589. PubMed ID: 36773054 [TBL] [Abstract][Full Text] [Related]
3. Tau phosphorylation and aggregation as a therapeutic target in tauopathies. Badiola N; Suárez-Calvet M; Lleó A CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789 [TBL] [Abstract][Full Text] [Related]
4. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884 [TBL] [Abstract][Full Text] [Related]
6. Further understanding of tau phosphorylation: implications for therapy. Medina M; Avila J Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397 [TBL] [Abstract][Full Text] [Related]
7. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087 [TBL] [Abstract][Full Text] [Related]
8. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. Stancu IC; Ferraiolo M; Terwel D; Dewachter I Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036 [TBL] [Abstract][Full Text] [Related]
9. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Bondulich MK; Guo T; Meehan C; Manion J; Rodriguez Martin T; Mitchell JC; Hortobagyi T; Yankova N; Stygelbout V; Brion JP; Noble W; Hanger DP Brain; 2016 Aug; 139(Pt 8):2290-306. PubMed ID: 27297240 [TBL] [Abstract][Full Text] [Related]
10. MK-8719, a Novel and Selective Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725 [TBL] [Abstract][Full Text] [Related]
11. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy. Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476 [TBL] [Abstract][Full Text] [Related]
12. Non-Canonical Roles of Tau and Their Contribution to Synaptic Dysfunction. Siano G; Falcicchia C; Origlia N; Cattaneo A; Di Primio C Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576308 [TBL] [Abstract][Full Text] [Related]
13. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies. Kyalu Ngoie Zola N; Balty C; Pyr Dit Ruys S; Vanparys AAT; Huyghe NDG; Herinckx G; Johanns M; Boyer E; Kienlen-Campard P; Rider MH; Vertommen D; Hanseeuw BJ Nat Commun; 2023 Jun; 14(1):3706. PubMed ID: 37349319 [TBL] [Abstract][Full Text] [Related]
14. Tauopathies: Mechanisms and Therapeutic Strategies. Tan CC; Zhang XY; Tan L; Yu JT J Alzheimers Dis; 2018; 61(2):487-508. PubMed ID: 29278892 [TBL] [Abstract][Full Text] [Related]
15. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Grinberg LT; Wang X; Wang C; Sohn PD; Theofilas P; Sidhu M; Arevalo JB; Heinsen H; Huang EJ; Rosen H; Miller BL; Gan L; Seeley WW Acta Neuropathol; 2013 Apr; 125(4):581-93. PubMed ID: 23371364 [TBL] [Abstract][Full Text] [Related]
16. Long COVID as a Tauopathy: Of "Brain Fog" and "Fusogen Storms". Sfera A; Rahman L; Zapata-Martín Del Campo CM; Kozlakidis Z Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628830 [TBL] [Abstract][Full Text] [Related]
17. Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome. Chaves-Filho AM; Braniff O; Angelova A; Deng Y; Tremblay MÈ Brain Res Bull; 2023 Sep; 201():110702. PubMed ID: 37423295 [TBL] [Abstract][Full Text] [Related]
18. Disease-modifying strategies in primary tauopathies. Rösler TW; Costa M; Höglinger GU Neuropharmacology; 2020 May; 167():107842. PubMed ID: 31704274 [TBL] [Abstract][Full Text] [Related]
19. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. Clavaguera F; Grueninger F; Tolnay M Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961 [TBL] [Abstract][Full Text] [Related]